Planep适应症

Eplerenone () is a new type of selective aldosterone receptor antagonist that was approved for clinical use by the US Food and Drug Administration in 2002. Eplerenone (Planep) indications: 1. Congestive heart failure after acute myocardial infarction: Eplerenone (Planep) can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that eplerenone (Planep) can also be used for heart failure after acute myocardial infarction and congestive heart failure after acute myocardial infarction; 2. Anti-hypertension: Eplerenone (Planep) can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension.

Eplerenone (Planep) was developed by Pfizer/Pharmacia under the trade name Inspra. It is a new generation of selective aldosterone antagonist. Eplerenone (Planep) has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Its outstanding advantage is that for severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone (Planep) can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. For patients with severe heart failure and myocardial infarction, eplerenone (Planep) combined with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve quality of life and reduce mortality.  

Clinical trials have shown that in the treatment of heart failure after acute myocardial infarction, eplerenone (Planep) can reduce the total mortality rate in the treatment group by 15% when used in combination with standard treatment drugs; eplerenone (Planep) is as effective as enalapril in reversing left ventricular hypertrophy and hypertension, with fewer cough side effects, and the combined effect is more obvious; eplerenone (Planep) has fewer adverse reactions, and except for the adverse reaction of increased blood potassium, other adverse reactions are no different from the placebo group; there are almost no sex hormone-related side effects of spironolactone.